1. A method for treating vascular-associated maculopathy in a subject comprising administering an effective amount of an inhibitor of elastase subektu.2. A method according to claim 1, characterized in that the elastase inhibitor is alpha-1 antitrypsin, ZD0892, SPIPm2, ONO-5046, 1,4-bisphenyl-1,4-dihydropyridine, 2-hydroxy and 2-aminodigidropiridinami, dolastatin or a dolastatin analogue or lingbiastatinom or analogue lingbiastatina.3. A method according to claim 1, characterized in that the elastase inhibitor to inhibit elastase activity HTRA 1.4. A method according to claim 3, characterized in that the elastase inhibitor is DPMFKLboroV.5. A method for treating (i) the vascular-associated maculopathy (Ii) treating one or more symptoms associated with vascular-associated maculopathy (Iii) treatment of maculopathy and severe maculopathy later stage, or (iv) aberrant resorption choriocapillaries fraction in a subject comprising administering an effective amount of an inhibitor of elastase subektu.6. A method according to claim 1, characterized in that the elastase inhibitor is alpha-1 antitrypsin, ZD0892, SPIPm2, ONO-5046, 1,4-bisphenyl-1,4-dihydropyridine, 2-hydroxy and 2-aminodigidropiridinami, dolastatin or a dolastatin analogue or lingbiastatinom or analogue lingbiastatina.7. A method according to claim 1, characterized in that the elastase inhibitor to inhibit elastase activity HTRA 1.8. A method according to claim 3, characterized in that the elastase inhibitor is DPMFKLboroV.9. A method for treating (i) the vascular-associated maculopathy (Ii) treating one or more symptoms associated with vascular-associated maculopathy (Iii) treatment of maculopathy and severe maculopathy later stage, or (iv) resorption aberrant fraction
